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A B S T R A C T
Real-time PCR are often used for the diagnosis and monitoring of Cytomegalovirus (CMV) and Epstein-Barr virus
(EBV) infections in susceptible populations. In this context, we evaluated the analytical performances of the
Abbott RealTime CMV/EBV maxCycle protocol automated on the m2000 platform (Abbott). It was compared to
our routinely-used procedure consisting of a NucleoMag® DNA extraction automated on a STARlet platform
followed by manually processed CMV and EBV quantitative real-time PCR (Diagenode). In this study, we showed
that both EBV assays exhibited a similar sensitivity but with a better precision for the EBV Abbott RealTime
assay. For the CMV performances, the Abbott assay was more sensitive and more precise than our routine
method. The use of WHO International Standards also indicated a slight underestimation of the viral loads
(−0.25 log10 IU/mL and −0.21 log10 IU/mL for CMV and EBV assays respectively) while these were rather
overestimated with the Starlet/Diagenode method (0.48 log10 IU/mL and 0.19 log10 IU/mL for CMV and EBV
assays respectively). These trends were confirmed using relevant whole-blood clinical samples and external
quality controls. The workflows were also compared and we highlighted a significant technician hands-on time
reduction (−63%) using the Abbott CMV/EBV maxCycle automated protocol.
1. Introduction
Automation plays an increasingly important role in the routine ac-
tivity of clinical laboratories, with the consolidation of specific activ-
ities such as biochemical analyses, hematology or serological diagnosis
through core-lab facilities (Hawker, 2007), with the development of
integrated solutions for bacteriological culture and antimicrobial sus-
ceptibility testing (Croxatto et al., 2016; Dauwalder et al., 2016), but
also in the molecular diagnostic field. This predictable change (Felder
et al., 1988) became a reality due to economic constraints, workload
pressure and the need for laboratories to deliver results in short turn-
around-times and has been made possible with the evolution of tech-
nology not only in large structures but also in smallest clinical labora-
tories.
In our university hospital (CHU), where many hematological and
solid organ transplantations are performed, two of the most important
analytical parameters conducted for the management of these patients
are the CMV and EBV viral load determinations. Cytomegalovirus
(CMV) and Epstein-Barr virus (EBV) are members of the Herpesviridae
family and are able to establish a life-long persistent and latent infec-
tion within their human host after primary infection. They are both able
to reactivate frequently throughout the lifespan and to disseminate
within the infected body. In immunocompromised patients, CMV re-
activation can lead to serious complications like allograft rejection
(Dioverti and Razonable, 2016) while EBV infection is associate to
malignant B cell lymphoproliferations (Martinez and Krams, 2017).
According to international guidelines, the use of quantitative EBV and
CMV PCR in blood is indicated in all hematopoietic stem cell transplant
(HSCT) or solid organ transplant (SOT) recipients to allow early in-
itiation of antiviral therapies and also for their monitoring (Gulley and
Tang, 2010; Heemann et al., 2011; Kotton et al., 2013; Torre-Cisneros
et al., 2016).
The increasing number of samples to be tested requires more and
more automated solutions in clinical laboratories. In this context, the
Abbot CMV and EBV RealTime assays automated on the Abbott m2000
platform were assessed and their analytical performances were
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compared to our currently used two-steps procedure consisting of a
NucleoMag® (Macherey-Nagel) whole-blood DNA extraction automated
on a STARlet platform (Hamilton) followed by a manually processed
quantitative real-time PCR using CMV and EBV commercial assays
(Diagenode). To achieve this, CMV and EBV WHO International
Standards were used as well as whole blood (WB) clinical samples and
several panels of external quality controls (QCMD). The Abbott
Realtime CMV/EBV maxCycle protocol allows the EBV and CMV viral
load determination in a single run. We have thus compared the work-
flow and the turnaround time (TAT) for WB samples using this CMV/
EBV maxCycle protocol to the routinely used Starlet/Diagenode method
in order to estimate the technical time saved when this full automated
Abbott protocol is used.
2. Materials and methods
2.1. Samples collection and standards
A total of 112 whole blood samples from 52 patients (34 males and
18 females, median age: 47.9 years, range: 5.5–73 years) hospitalized in
our institution were collected in EDTA tubes and included in this study.
Samples were stored at 4°c before being processed. PCR were performed
on both platforms within a median delay of 1 day (interval: 1 to 8.5
days) and 3 days (interval: 1 to 6 days) for CMV and EBV analysis re-
spectively. WHO International Standards (IS) from the National
Institute for Biological Standards and Controls (NIBSC, Hertfordshire,
United-Kingdom) were used in this study: the 1st WHO International
Standard for HCMV for Nucleic Acid Amplification Techniques (NIBSC
code: 09/162) comprised a whole virus preparation of the HCMV
Merlin strain while the 1st WHO International Standard for EBV for
Nucleic Acid Amplification Techniques (NIBSC code: 09/260) com-
prises a whole virus preparation of the EBV B95-8 strain (type 1).
Several panels of external controls from the Quality Controls for
Molecular Diagnostics organization (QCMD, Glasgow, UK) were also
used in this study (CMVWB16C1, EBVWB15C2 and EBVWB16C1).
These controls were processed as clinical samples and their viral loads
were assessed on both platforms in parallel.
2.2. Whole blood extraction and Real-Time PCR using the Starlet/
Diagenode system
Whole-blood DNA extraction was performed using the NucleoMag®
Blood 200 μL kit (Macherey-Nagel GmbH &Co.KU, Düren, Germany)
automated on a STARlet platform (Hamilton) following manufacturer’s
instructions Briefly, 200 μL of whole blood were lysated in a buffer
containing proteinase K and paramagnetic beads were used to remove
contaminants and salt while elution was performed using a low-salt
buffer. In its home-made configuration, the STARlet platform allows the
automated DNA extraction of 80 samples in a single run.
EBV and CMV DNA quantification were performed using the
Diagenode Real-Time quantitative PCR kits (Dia-EBVQ-050 and Dia-
CMVQ-050 respectively, Diagenode, Seraing, Belgium) following man-
ufacturer’s recommendation. Distribution of the Diagenode Internal
Control (DNA virus culture) for extraction in each sample was per-
formed using the STARlet platform before extraction. Mastermix addi-
tions (20 μL) to the eluated DNA (5 μl) were done manually and the RT-
PCR runs were performed on an ABI7500 thermocycler (Thermo Fisher
Scientific, Waltham, USA). When the EBV and CMV quantifications
were requested for the same sample, a single extraction was performed
on the STARlet platform for this sample and the EBV and CMV PCR
were run separately. Quantifications were achieved for both tests by
comparing Ct values obtained for each samples to a specific 5 points
calibration curve established for each run. Results are expressed in
copies/mL for EBV and CMV or in International Units (IU)/mL for CMV
only. According to the manufacturer, the limit of detection (LOD) for
the Diagenode CMV test was 820 IU/mL (2.91 log10 IU/mL) and 822
copies/mL for the Diagenode EBV test when samples were extracted
using an EasyMag (Biomerieux) and PCR performed on a LC480
(Roche) or a CFX96 (Biorad) thermocycler respectively. Since the
manufacturer provided no information on the Limit of Quantification
(LOQ) for these tests, we extrapolated them as being equal to the LOD.
2.3. EBV and CMV quantification using the Abbott m2000 platform
The Abbott m2000 system used was a 2-parts platform composed of
extraction (m2000sp) and detection automates (m2000rt). The
m2000sp allowed the simultaneous extraction of 48 samples for EBV or
CMV quantification as well as the automated distribution of eluated
DNA and mastermix in a RT-PCR plate. DNA extractions were per-
formed using the Abbott mSample Preparation SystemDNA. The Abbott
RealTime CMV/EBV maxCycle protocol was used for this study: it al-
lowed the management of CMV and EBV samples in a single run but
required a specific extraction for each test, in two different tubes, when
both of these parameters were requested at the same time. The ex-
traction procedure required at least 300 μL of whole blood (plus 200 μL
of dead volume) and was based on a detergent and guanidium thio-
cyanate lysis with the use of magnetic microparticles to isolate nucleic
acids. A non-infectious linearized plasmid was used as internal inhibi-
tion control and was added to each sample within the mlysisDNA buffer.
The Abbott RealTime CMV Control kit was composed of a negative
sample and a positive one while for the EBV test a negative control and
two positive ones (low and high) must be included in the calibration
run. Determinations of the viral loads were calculated using calibration
curves established via 2 points in replicates of three and expressed in
IU/mL or log10 IU/mL for both tests but also in copies/mL or log10
copies/mL for the CMV assay only. These curves stored in the software
were valid for a period of maximum 6 months. The announced limits of
detection for the Abbott whole blood assays were respectively 62 IU/
mL (1.79 log10 IU/mL) for the CMV test and 150 IU/mL (2.18 log10 IU/
mL) for the EBV assay. In both cases, the lower limits of quantification
were equivalent to the limit of detection of these viruses.
2.4. CMV and EBV conversion factors
For the EBV Diagenode assay, results were expressed in copies/mL
only and there was no conversion factor provided by the manufacturer
while for the EBV Abbott assay, results were provided in IU/mL only.
We have thus established a copy-to-IU conversion factor for the EBV
Diagenode assay using the 1st WHO International Standard for EBV for
Nucleic Acid Amplification Techniques (IS), in order to compare these
results with those obtained on the Abbott platform. The conversion
factor was established based on Semenova et al. protocol and was the
geometric mean of 16 individual viral loads determination of a range of
dilutions (4 sets of 4 dilutions above the LOQ) in negative whole blood
from the EBV WHO IS and the given value of this International Standard
(Semenova et al., 2016). Two different lots of amplification reagents
were used for this. The results in copies/mL have to be multiplied by
this conversion factor to obtain those results in IU/mL. The same pro-
cedure was used with the 1st WHO International Standard for CMV for
Nucleic Acid Amplification Techniques to calculate the copy to IU
conversion factor for the Abbott CMV and Diagenode assays and to
compare them to those proposed by the manufacturers.
2.5. Evaluation of the analytical performances
The analytical performances of theses assays were assessed using
WHO International Standards and clinical samples. The WHO
International Standards were reconstituted in 1ml nuclease free water
to achieve a concentration of 5.106 IU/mL. Serial dilution ranging from
5.3 to 0.3 log10 IU/mL of these WHO controls were performed in ne-
gative whole blood samples. EBV and CMV status of these negative
whole blood samples were previously checked on both platforms used
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in this study. These dilutions were tested in parallel on both system in at
least replicates of 4, at different times, to determine the sensitivity, the
lower limit of quantification (LLQ), the accuracy and the precision of
the CMV and EBV assays. We defined the sensitivity and the LLQ as the
lowest viral concentration detected or quantified in 100% of the re-
plicates tested respectively. The mean differences between the theore-
tical viral loads for each WHO IS dilution and those measured from the
highest concentration to the LLQ on the systems were calculated in
order to evaluate the accuracy of both systems. The precision of these
assays was reflected by the mean of the standard deviations (SD) cal-
culated for each replicated single point. Raw data obtained during the
validation procedure with the WHO IS are available here [dataset]
(Bontems et al., 2019).
2.6. Statistics
All statistical analyses were performed with the R program version
3.3.2 from the R Foundation for Statistical Computing Platform (R Core
Team (2016), n.d.). The linearity of the relation between the theoretical
concentration of the WHO International Controls and the Ct values
obtained for the different real-time PCR as a quality control of the
preparation of the dilution curves was evaluated with this program by
the calculation of a coefficient of determination for each curves (r²).
The degree of agreement between the measured viral loads in positive
samples tested on both platforms was evaluated with the Spearman’s
rank correlation coefficient (rs). The normality of quantitative data was
investigated graphically and using the Shapiro test. The pairwise t-test
was used to calculate and to examine the relevance of the differences
within the mean values in positive samples obtained with both plat-
forms for the tests used as well as to define a 95% confidence interval
(CI) for this test. In the statistical hypothesis testings performed in this
study, the significance level was set to 0.05 (5%).
3. Results
3.1. Comparison of CMV analytical performances using WHO International
Standards (WHO IS)
The results of this validation unambiguously showed a better sen-
sitivity (defined as a 95% detection rate) when the CMV viral load is
measured on the m2000 platform rather than on our routine Starlet/
Diagenode system: the lowest CMV concentration detected (LLD) was
1.11 log10 IU/mL for the Abbott CMV assay and 3.20 log10 IU/mL for
the CMV Starlet/Diagenode. The lower limit of quantification (LLQ)
was also better with the CMV Abbott assay (2.51 log10 IU/mL vs 3.20
log10 IU/mL). The difference between the theoretical viral loads using
WHO IS dilutions and those measured on the systems were compared in
order to evaluate the accuracy of both system: in the linear range tested,
the viral loads were slightly underestimated with the CMV Abbott assay
(−0.25 log10 IU/mL; SD=0.32) while they were rather overestimated
when the Starlet/Diagenode system was used (+0.48 log10 IU/mL;
SD=0.15) (Fig. 1). The precision of these assays, reflected by the
means of the standard deviations (SD) calculated for each replicated
single point, was better with the Abbott RealTime platform (0.16 log10
IU/mL +/− 4.82%) than using our routine CMV Starlet/Diagenode
protocol for the CMV PCR (0.33 log10 IU/mL +/− 7%). We also
compared the observed variations in the Ct values of the respective
internal controls used in the two tests and we showed that this variation
was also lower on the Abbott platform (CV=0.99%) than using the
Starlet/Diagenode system (CV=2.4%). For the Abbott CMV assay, the
manufacturer has established a unique copy-to-IU conversion factor for
both plasma and whole blood matrix (1 copy= 1.56 IU). In this study,
CMV WHO IS were used to evaluate this conversion factor and it was
established that 1 copy=2.5 IU. For the Diagenode CMV assay, the
manufacturer has established a copy-to-IU conversion factor using also
the CMV WHO IS (NIBSC code 09/162) where 1 copy=1.2 IU. In our
study, the use of this CMV IS allowed us to established that 1 copy=
0.41 IU.
3.2. Comparison of EBV analytical performances using WHO International
Standards
Abbott EBV results are reported in International Units/mL but in the
Diagenode test, results are delivered in copies/mL. To be able to fully
confront them, we used the WHO IS standards to determine a copy to IU
conversion factor for the Diagenode EBV assay. This conversion factor
was established to be 1 copy= 0.77 IU and was used to convert all viral
loads expressed in copies/mL with the EBV Starlet/Diagenode platform
to IU/mL. Thus, the commercially announced LLD of 822 copies/mL
was 633 IU/mL (2.8 log10 IU/mL). Using decreasing concentrations of
the EBV WHO IS spiked in negative whole blood we showed that the
measured LLD for the Diagenode assay was better than announced (65
IU/mL or 1.81 log10 IU/mL) and similar to the Abbott EBV assay while
the LLQ with the Starlet/Diagenode method was better (1.81 log10 IU/
mL) than with the Abbott one (2.51 log10 IU/mL) (Fig. 1). As for the
CMV assay, the EBV Abbott assay exhibited a slight underestimation of
the viral loads (-0.21 log10 IU/mL; SD=0.21), while the viral loads
obtained on the Starlet/Diagenode platform were slightly over-
estimated, especially at low viral loads, with an accuracy for this test of
0.19 log10 IU/mL (SD=0.23). The precision of these assays was also
better with the Abbott RealTime platform (0.19 log10 IU/mL +/−
5.18%) than using our routine CMV Starlet/Diagenode protocol for the
EBV PCR (0.43 log10 IU/mL +/− 11.83%).
3.3. Comparison of CMV analytical performances using clinical samples
and QCMD
Eighty-six whole-blood clinical samples coming from our institution
were challenged on both systems. Out of these samples, 38 (44%) were
detected using our routine CMV Starlet/Diagenode system including 15
samples (17%) under the announced limit of quantification (LOQ) and
23 quantified (quantification rate= 27%) (Fig. 2). When these 86
samples were proceeded on the Abbott m2000 platform, 48 (56%) were
detected using this CMV assay including 6 samples (7%) under the limit
of quantification of the test while the quantification rate was 49% (42
samples) with this method. Among the discrepancy results, 12 samples
quantified by the Abbott system (viral loads ranging from 96 to 1207
IU/mL) were under the LOQ (820 IU/mL) of the CMV Diagenode test
and 8 samples were only detected with the CMV Abbott assay (viral
loads ranging from 78 to 312 IU/mL). Out of these 20 samples, 10 of
them quantified by the Abbott system had a viral load greater than our
locally defined treatment threshold for CMV (1000 copies/mL) sug-
gesting that the corresponding patients would have been considered for
treatment if the Abbott system had been used routinely at that moment
with the same threshold.
Twenty-two samples (25%) were quantified using both methods and
the statistical analysis of the results showed that these methods were
correlated (p=0.0002, rs= 0.72). However, the mean difference
(bias) between both test was 0.79 log10 IU/mL, indicating that the viral
loads measured with the Starlet/Diagenode system were on average
0.79 log10 IU/mL higher than those measured with the CMV Abbott
assay, and this difference was statistically significant (p-value=
6.10−6) (Fig. 3). As a consequence, 5 of the 22 samples quantified by
the Starlet/Diagenode system had a viral load above the treatment
threshold but fell below this threshold when quantified using the Ab-
bott system.
To address the signification of this difference in terms of follow-up
of patients, successive samples were collected at different times and the
CMV viral load measured using those two techniques. The graphically-
presented results showed that replication kinetics of the viral load
measured for these patients were similar using both methods but that
the sensitivity of the CMV Abbott assay was often better for low viral
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loads while the viral load peaks were more pronounced when measured
with the Starlet/Diagenode system (Fig. 4).
These observations were also confirmed using external controls
from the Quality Controls for Molecular Diagnostics (QCMD) organi-
zation: out of the 15 samples tested, all were correctly evaluated with
the Abbott assay (100% detection rate and all viral loads measured felt
within 1 Standard Deviation (SD) of the consensus values) while using
the Starlet/Diagenode system 2 low positive samples were not detected,
4 quantified samples had a measured viral load above 1 SD and 1
quantified sample had a viral load above 2SD of the mean consensus
value confirming the overestimation of the viral loads when the Starlet/
Diagenode protocol was used (Table 1).
Fig. 1. Accuracy and precision of the CMV and EBV assays on the Abbott m2000 and the Starlet/Diagenode platforms using serial dilutions of WHO International
Controls (ranging from 5.3 to 0.3 log10 IU/mL). Only dilutions with 100% quantification rate between replicates of four are represented (blue dots). The mean
differences between the observed and the expected viral loads are plotted and the standard deviations presented. Grey zones= under the announced limit of
quantification (LOQ) of the tests.
Fig. 2. CMV and EBV detection and quantification in clinical samples using the Abbott m2000 vs the Starlet/Diagenode system. N=number of
samples. < LOQ=under the limit of quantification of the assay.
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3.4. Comparison of EBV analytical performances using clinical samples and
QCMD
For the evaluation of the Abbott EBV assay, 86 samples from 46
patients were collected and tested in parallel with both systems. Out of
these 86 samples, 52 (60.5%) were detected with 34 samples quantified
(39.5%) and 18 (21%) under the commercially announced LOQ with
the Starlet/Diagenode system while 54 were detected (63%) with a
quantification rate of 49% (42 samples) while 12 samples (14%) were
under the LOQ with the Abbott EBV assay. Among the discrepancy
samples, 10 samples were quantified by the Abbott assay (viral loads
ranging from 189 to 1570 IU/mL) but were under the announced LOQ
of the Diagenode assay (663 IU/mL). Moreover, 1 sample was not de-
tected by the Starlet/Diagenode system but quantified using the Abbott
assay with a detected viral load of 1090 IU/mL (see Fig. 2). Fourteen
samples quantified by the Abbott system had a viral load greater than
our locally defined treatment threshold for EBV (1000 copies/mL),
unlike with the Starlet/Diagenode one where most of these samples
were under the LOQ (820 IU/mL). Conversely, 4 samples had a viral
load under the treatment threshold when measured on the Abbott
platform, unlike with the Starlet/Diagenode system.
Out of the 86 samples tested, 31 (36%) were quantified using both
methods and the calculated correlation coefficient has indicated that
both methods were correlated (rs= 0.75, p-value<0,0001). The mean
difference between both test was 0.18 log10 IU/mL indicating that the
viral loads measured with the Starlet/Diagenode system were on
average slightly higher than those measured with the EBV Abbott assay
and this difference was statistically significant (p-value=0.03) (Fig. 3).
The follow-up of EBV among positive patients was conducted and it
can be shown on the representative patients presented on Fig. 4 that the
EBV viral load kinetics were rather similar when performed on both
systems. This was also confirmed using external controls from the
Quality Controls for Molecular Diagnostics (QCMD) organization: out of
the 10 samples tested, all were correctly evaluated with both methods
(100% detection rate). One sample had a measured viral load above 1
SD of the consensus value with the Abbott assay and two with the
Starlet/Diagenode system (Table 1).
3.5. Comparison of the workflows using the Abbott EBV/CMV maxCycle
and the Starlet/Diagenode protocols
The workflows and the turnaround time (TAT) to process WB
samples were evaluated on the automated Abbott m2000 platform using
the Abbott Realtime CMV/EBV maxCycle protocol and compared to the
Starlet/Diagenode system. In both cases, CMV and EBV assays can be
processed in a single run but two separate extractions must be per-
formed on the m2000sp on a split sample (or on duplicated primary
samples) if both CMV and EBV viral loads are requested for a single
patient. To evaluate this, the overall process was divided in 5 steps and
the mean time to complete each step, reported per sample, was mea-
sured during 4 runs of 50% EBV and 50% CMV samples by distin-
guishing manual from automated procedures (Fig. 5). Our results in-
dicated that the TAT per sample was slightly increased (+11.5%) using
the Abbott platform (10.60 +/− 0.14min/sample vs. 9.50 +/−
0.17min/sample) rather than the Starlet/Diagenode procedure. The
main reason was that the Abbott platform could only handle a max-
imum of 48 samples (including controls) at the same time while 80
samples (including controls) can be processed using the Starlet/Diag-
enode protocol in a single run. However, we clearly observed that there
was a reduction of about 62.8% of the technical hands-on time (HAT)
with the Abbott system compared to the Starlet/Diagenode one. The
number of manual interventions was much higher with the Starlet/
Fig. 3. Bland-Altman analysis of the CMV and
EBV assays performed on the Starlet/
Diagenode and the Abbott RealTime systems
for the 22 (CMV) and 31 (EBV) positive clinical
samples. Agreement between two methods is
met if≥95% of the samples are found between
+/- 1.96 SD (dotted lines) from the mean
difference (bias; dashed line) (Bland and
Altman, 2007). CMV (21/22; 95.4%) and EBV
(33/33; 100%) assays met this criterion.
Fig. 4. Kinetics of CMV and EBV viral loads in
patients follow-up. The dotted colored lines are
the limits of quantification (LOQ) of the tests
(blue=Abbott m2000, green= Starlet/
Diagenode). Samples with CMV or EBV de-
tected but under the LOQ are represented by
red squares (for the Starlet/Diagenode test) or
red diamond (for the Abbott assay) on the
corresponding dotted line. Black spots re-
present samples with an undetected viral load.
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Diagenode system, meaning that more technical resources were re-
quired to complete these tasks. It was noticeable for the mastermix
preparation step, its addition to the DNA extracts as well as for the data
management, including the internal controls analysis and the transfer of
the results to the LIS system.
4. Discussion & conclusions
In this study, we evaluated the CMV and EBV RealTime PCR assays
proposed by Abbott on the m2000 platform using the CMV/EBV
maxCycle protocol allowing the execution of these two assays in a
single run. Our reference technique for this evaluation was our routi-
nely-used two-steps procedure consisting of a NucleoMag® (Macherey-
Nagel) whole-blood DNA extraction automated on a STARlet platform
(Hamilton) followed by a manually processed quantitative real time
PCR using CMV and EBV assays (Diagenode). The search for a more
automated solution for these assays was motivated by the desire to
improve the performances of our routinely-used assays but also to re-
duce the technician’s hands-on time. Several studies have already been
published in this context to compare the performances of manually
processed and automated real-time PCR solutions available to detect or
quantified different pathogens in clinical samples and/or WHO stan-
dards (Engelmann et al., 2019, 2018; Furione et al., 2012; Vinuesa
et al., 2017).
We showed that the analytical performances of the Abbott CMV and
EBV assays were satisfying and overall improved compared to our
routinely-used method, with a variability of the viral loads measured
lower with the Abbott assays (mean of SD=0.16 log10 IU/mL vs 0.33
log10 IU/mL for CMV and 0.19 log10 IU/mL vs 0.43 log10 IU/mL for
EBV), in accordance to the performances announced by the manu-
facturer (inter-assay mean of SD=0.09 log10 IU/mL and 0.14 log10 IU/
mL respectively; see package inserts) and also in agreement with other
studies for CMV (Schnepf et al., 2013) and EBV (Salmona et al., 2016).
To our knowledge, this study is the first one evaluating the accuracy, as
well as the sensitivity, of the Abbott RealTime EBV assay using WHO IS.
Concerning the accuracy of the CMV Abbott RealTime assay, Schnepf
et al. have evaluated it using QCMD controls as being also slightly lower
than expected with a mean difference between measured and expected
values of -0.26 log10 copies/mL (Schnepf et al., 2013) while Tsai et al.
observed a bias of 0.141 log10 IU/ml when CMVWHO IS were used, this
late being performed with the plasma extraction protocol unlike our
study (Tsai et al., 2016). The results obtained at the QCMD external
controls challenges for CMV and EBV were also satisfying, reinforcing
the idea that both tests are reliable and accurate. It must be also noted
that during this validation procedure, no clinical sample tested failed
using the Abbott platform (e.g. internal control out of range). With the
Starlet/Diagenode system we had a measured failure rate of 4% (data
not shown), but mostly due to pipetting errors. The follow-up of several
CMV and EBV positive patients showed that the kinetics of the viral
loads were rather similar, but with a marked overestimation of the CMV
load when the Starlet/Diagenode system was used. This can have an
impact on the patient care and must be considered if they are based on
locally defined treatment thresholds.
Expression of the viral loads in International Units is more and more
advised for clinical laboratories: in a survey conducted by the European
Study Group of Infections in Immunocompromised Hosts (ESGICH),
data collected have clearly revealed that if a large part of the centers
questioned systematically use quantitative real-time PCR for CMV
monitoring (99.4%), only 30% of them reported the DNA loads in IU/
mL while the majority (63.6%) reported it in copies/mL (Navarro et al.,
2017). This study has also revealed that most clinicians questioned
(82.5%) started preemptive antiviral treatment when CMV DNA load
Table 1
QCMD CMV and EBV challenges. The EQA (External Quality Assessment) consensus viral loads as well as the standard deviations (SD) are indicated for each sample
either in copies/mL or in IU/mL. Δ = difference between measured and expected viral loads, Ndt=Not detected.
QCMD CMV Starlet/Diagenode Abbott
EQA Consensus SD Results Δ Results Δ
log10 cop/mL log10 cop/mL log10 cop/mL
CMVWB15C1-01 2,17 0,62 Ndt / 1,99 −0,17
CMVWB15C1-02 3,05 0,44 3,00 −0,05 2,69 −0,36
CMVWB15C1-03 3,08 0,42 3,28 0,21 2,81 −0,26
CMVWB15C1-04 – – Ndt – Ndt –
CMVWB15C1-05 2,99 0,37 2,79 −0,20 2,91 −0,08
CMVWB15C2-01 2,64 0,36 2,22 −0,42 2,30 −0,34
CMVWB15C2-02 2,05 0,39 Ndt / 1,78 −0,27
CMVWB15C2-03 3,56 0,29 4,16 0,61 3,35 −0,21
CMVWB15C2-04 – – Ndt – Ndt –
CMVWB15C2-05 2,90 0,36 3,48 0,58 2,77 −0,13
CMVWB16C1-01 2,92 0,41 3,09 0,17 3,11 0,19
CMVWB16C1-02 – – Ndt – Ndt –
CMVWB16C1-03 2,82 0,45 3,29 0,47 2,75 −0,07
CMVWB16C1-04 2,77 0,50 2,97 0,20 2,68 −0,09
CMVWB16C1-05 2,40 0,45 2,88 0,48 2,46 0,06
QCMD EBV Starlet/Diag QCMD EBV Abbott
EQA Consensus SD Results Δ EQA Consensus SD Results Δ
log10 cop/mL log10 cop/mL log10IU/mL log10 IU/mL
EBVWB15C2-01 3,49 0,46 3,85 0,36 3,67 0,12 3,64 −0,03
EBVWB15C2-02 3,08 0,44 3,23 0,15 3,19 0,10 3,33 0,14
EBVWB15C2-03 3,99 0,38 4,19 0,19 4,15 0,14 4,12 −0,03
EBVWB15C2-04 – – – – – – – –
EBVWB15C2-05 2,73 0,54 2,97 0,24 2,56 0,15 2,43 −0,13
EBVWB16C1-01 3,51 0,44 4,11 0,60 3,74 0,12 3,65 −0,09
EBVWB16C1-02 3,22 0,61 3,78 0,56 2,65 0,46 2,22 −0,43
EBVWB16C1-03 – – – – – – – –
EBVWB16C1-04 2,40 0,57 2,48 0,08 2,18 0,00 2,18 0,00
EBVWB16C1-05 3,55 0,43 4,00 0,45 3,79 0,14 3,72 −0,07
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exceeded a predefined and locally validated cut-off. This late varies
from 100 to> 100.000 IU/mL when whole blood specimens are used,
with a commonly used 1000 CMV DNA IU/mL threshold. As a con-
sequence, CMV load determination must be carried out with the same
assay, on the same matrix and in the same center when patient mon-
itoring is performed. It also highlights the importance of a constant
dialogue with the clinicians when such a change of method is being
considered by a clinical laboratory. In our institution, a careful follow-
up of the patients was made during several weeks after the routine
implementation of the Abbott platform and new therapeutic thresholds
were defined in agreement with the clinicians and based on our local
experience.
The Abbott RealTime CMV/EBV maxCycle protocol provides results
in IU/mL or in copies/mL for the CMV assay but only in IU/mL for the
EBV one, unlike the version 1.0 of this assay. We have calculated in this
study, although with a limited number of replicates, a copy-to-IU con-
version factor for the CMV assay using the WHO IS diluted in whole
blood and we have shown that it was slightly higher (1copy=2.5 IU)
than the one provided by the manufacturer for the plasma and the
whole blood (WB) specimen (1copy= 1.4 IU). Other studies have de-
termined more divergent conversion factors for the same assay using
also WHO IS in WB as reference: Schnepf et al. have calculated a con-
version factor where 1 copy= 0.46 IU when the WHO IS was diluted in
whole blood and 1 copy= 0.86 IU when it was diluted in PBS while
Furione et al. have calculated a conversion factor where 1 copy=7.69
IU in WB (Furione et al., 2012; Schnepf et al., 2013). We have also
calculated a conversion factor for the Diagenode CMV assay (1copy=
0.41 IU) and showed that it was divergent to the one provided by the
manufacturer (1copy=1.2 IU). The origin of these discrepancies could
be found in the absence of a detailed and consensual protocol to cal-
culate the conversion factor according to the assay as well to the matrix
used (Schnepf et al., 2013) but also in the nature of the standards used.
The absence of commutable International Standards (IS) prevented for
many years the establishment of clinical thresholds for therapeutic
decisions due to the high variability observed between the different
techniques or matrix used for the viral loads determination and to the
absence of harmonization of these tests (Caliendo et al., 2009; Wolff
et al., 2009). EBV (Fryer et al., 2016b) and CMV(Fryer et al., 2016a)
WHO International Standards were developed to meet the needs ex-
pressed in this way in the guidelines and the recommendations made by
the healthcare professionals (Andrews et al., 2011; Gulley and Tang,
2010; Heemann et al., 2011; Kim et al., 2017; Kotton et al., 2013;
Navarro et al., 2017; Torre-Cisneros et al., 2016; Wattles et al., 2017).
However, the commutability of the EBV (Abeynayake et al., 2014; Ruf
and Wagner, 2013; Tang et al., 2016) and CMV (Fryer et al., 2016c;
Hayden et al., 2015, 2013) WHO IS was examined and questioned. For
instance, Preiksaitis et al. conducted a study using 10 different qPCR
assays calibrated to the IS and they determined the viral loads of serial
IS dilutions and a blinded panel of CMV positive and negative clinical
samples. They reported that variations were somewhat limited by the
use of the IS as reference to calibrate the assays, but a significant
variability was still observed mostly for clinical samples. The origin of
this variability is still not well-defined, linked to the size of the am-
plicons detected by the different assays but mostly multifactorial
Fig. 5. Comparison of the workflows for the CMV and EBV
viral load determination using the Abbott EBV/CMV maxCycle
and the Starlet/Diagenode protocols by distinguishing manual
from automated procedures. The mean time for each step was
related per sample. SP= samples process, including samples
sorting, aliquoting, tube labeling and the generation of the
working lists. Extraction= extraction procedure including the
pre- and the post-run maintenances, reactive, disposables and
samples loadings. MMX=Mastermix preparation and addi-
tion to the DNA samples. Data MGMT=Data management,
including the controls analysis and the LIS transfer.
HAT= technical hands-on time.
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(Preiksaitis et al., 2016).
One of the stated goals of lab automation is to save time to increase
either the productivity of the laboratories or to dedicate technical re-
sources to more specific and/or valuable tasks. In this study we have
estimated that the use of the Abbott RealTime CMV/EBV maxCycle
protocol increases the turnaround time (TAT) of about 11.5% compared
to our previous system. The main reason is that the Abbott platform can
only process a maximum of 48 samples (including controls) at the same
time which is nearly half of the samples that can be processed using the
Starlet/Diagenode protocol. Moreover, the protocols for the DNA ex-
traction as well as for the PCR are longer than with the Starlet/
Diagenode system. However, we observed a technician hands-on time
reduction of more than 60% using the Abbott platform due to the high
automation of this system. It is noticeable for the mastermix prepara-
tion and assembly as well as for the data management processes. It must
be noted that if the Abbott RealTime CMV/EBV maxCycle protocol al-
lows the extraction of both CMV and EBV in the same run, two separate
extractions must be performed on a split sample (or on duplicated
primary samples) if both CMV and EBV viral loads are requested for a
single patient. Interestingly, the CMV/EBV maxCycle protocol also uses
the Abbott mPLUS feature that allows the tracking of the number of
tests used as well as the tests remaining within an amplification pack.
This feature greatly increases the flexibility of the Abbott m2000 plat-
form (Lucic et al., 2013).
In conclusion, the results presented in this study indicate that the
Abbott RealTime CMV/EBV maxCycle protocol is functional, reliable
and accurate when these assays are performed on blood samples, that it
allows a reduction of the technical hands-on time, a significant increase
in the quality of the results and their delivery in International Units for
both assays.
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